For HIV-1 treatment in HTE* adults
If their regimen fails,
we'll be there
A first-in-class treatment with a novel mechanism of action1,2
For HIV-1 treatmentin HTE* adults
If their regimen fails,
we'll be there
A first-in-class
treatment with a novel
mechanism of action1,2

INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.
*Heavily treatment-experienced.
Sign Up for our next webinar
DISCOVER RUKOBIA
BRIGHTE CLINICAL
TRIALLearn about the efficacy and safety of RUKOBIA in BRIGHTE
DOSING AND DRUG
INTERACTIONSLearn about administering RUKOBIA
ViiV MEDICAL
INFORMATIONView our medical information library if you have a question about RUKOBIA
A DEEPER LOOK AT RUKOBIA
RISKS & SIDE EFFECTS
Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation
A NOVEL
MECHANISM
OF ACTION
Learn what makes RUKOBIA a first-in-class HIV-1 attachment inhibitor1,2
EDUCATIONAL RESOURCES
View educational library for RUKOBIA, including videos and a downloadable resource
References:
- Data on file, ViiV Healthcare.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed March 3, 2020.
FSTWCNT200018